GoodRx (Nasdaq: GDRX) announced it is working with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy in ...

Neffy, an intranasal formulation of epinephrine, is now available for emergency treatment of type I allergic reactions.

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS ...

Last week the FDA approved Neffy, an epinephrine nasal spray, for use in emergency allergic reactions for kids and adults. Retired allergist at the Northwest Asthma & Allergy Center Paul Williams ...

Whether it’s allergies, a sinus infection or runny nose, many people turn to nasal sprays for quick relief. Now, there’s ...

ARS Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) for a1 mg dose of nasal spray neffy, to treat ...

The submission of the neffy 1 mg sNDA follows the FDA approval of neffy (2 mg) on August 9, 2024, for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 kg ...

ARS Pharmaceuticals' neffy, a needle-free nasal spray for Type I allergic reactions, received early FDA approval, driving a 120% YTD share price increase. Neffy addresses a significant unmet need ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Rubin is a pediatrician specializing in allergy and immunology.

It’s called Neffy and it’s an epinephrine nasal spray. Epinephrine is the only life-saving treatment for anaphylaxis and, until now, was administered via a needle in an auto-injector like the ...

Credit: ARS Pharmaceuticals. Neffy is indicated for adult and pediatric patients weighing at least 30kg. It is recommended that patients be prescribed and have immediate access to 2 neffy nasal ...